Yakuchinone A
Yakuchinone A has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, May 8, 2026: “Yakuchinone A alleviates hepatic ischemia-reperfusion injury in aging livers via the SESN2/AKT1/NRF2 pathway”.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Hainan Medical University and 1 more
- Animals1
What did studies of Yakuchinone A find?
3Studies of Yakuchinone A measured 3 outcomes; the most studied are SESN2 (1 study), ferroptosis (1) and hepatic ischemia reperfusion injury (1).
SESN2
upin mice1
1 study
SESN2
upin mice1
Yakuchinone A increases SESN2 in mice.
“YakA treatment significantly upregulated SESN2 expression and reactivated the AKT1/NRF2 defense cascade.”
Animalsliver
International immunopharmacology
Ferroptosis
downin mice1
1 study
Ferroptosis
downin mice1
Yakuchinone A inhibits ferroptosis in mice.
“YakA protects livers from ischemia-reperfusion injury by targeting the SESN2/AKT1/NRF2 pathway to inhibit ferroptosis.”
Animalsliver
International immunopharmacology
Hepatic ischemia reperfusion injury
downin mice1
1 study
Hepatic ischemia reperfusion injury
downin mice1
Yakuchinone A protects against hepatic ischemia reperfusion injury in mice.
“YakA protects livers from ischemia-reperfusion injury by targeting the SESN2/AKT1/NRF2 pathway to inhibit ferroptosis.”
Animalsin aged mice with hepatic ischemia-reperfusion injuryliver
International immunopharmacology